Guttman-Yassky E, Weidinger S, Simpson E, Gooderham M, Irvine A, Spelman L, Silverberg J, Elmaraghy H, DeLuca-Carter L, Buziqui Piruzeli ML, Hu C, Yang FE, Pierce E, Bardolet L, Thaci D. Efficacy and Safety of Lebrikizumab Is Maintained to Two Years in Patients With Moderate-to-Severe Atopic Dermatitis. J of Skin [Internet]. 2023 Nov. 13 [cited 2024 Jul. 3];7(6):s271. Available from: https://jofskin.org/33014/index.php/skin/article/view/2382